Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Combination Regimen Grazoprevir (MK-5172) and Elbasvir (MK-8742) ± Ribavirin in Participants With Chronic Hepatitis C (MK-5172-035)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 20.0

Eligibility Criteria:
Inclusion criteria:~All participants~* CHC genotype 1 (GT1) virus infection (Parts A, B, and C) or GT3 virus infection (Part D)~* Female participants of childbearing potential or male participant with female partners of childbearing potential, must use two acceptable methods of birth control from ≥2 weeks prior to Day 1 until ≥6 months after last dose of study drug, or longer if dictated by local regulations~Part A - Absence (no medical history or physical findings) of ascites, bleeding esophageal varices, hepatic encephalopathy, or other signs or symptoms of advanced liver disease, or cirrhosis - No evidence of advanced fibrosis, cirrhosis and/or hepatocellular carcinoma by biopsy or noninvasive testing (FibroScan and/or FibroTest)~Parts B, C, and D~* Treatment naïve with or without cirrhosis, or~* Prior treatment failure to Peg-IFN/Ribavirin with or without cirrhosis, or~* Co-infected with human immunodeficiency virus (HIV) without cirrhosis~* Absence (no medical history or physical findings) of ascites, bleeding esophageal varices, hepatic encephalopathy, or other signs or symptoms of advanced liver disease~* Liver disease staging assessment by liver biopsy or noninvasive testing (FibroScan and/or FibroTest)~Exclusion criteria:~All participants~* Non-GT1 HCV infection (Part A, Part B, and Part C) or a non-GT3 HCV infection (Part D) including a mixed GT infection (with a non-GT1 \[Part A, Part B, and Part C\] or non-GT3 \[Part D\]) or a non-typeable genotype~* Evidence of hepatocellular carcinoma (HCC) or is under evaluation for HCC~* Currently participating or participated in a study with an investigational compound within 30 days of signing informed consent and is not willing to refrain from participating in another study~* Diabetic and/or hypertensive with clinically significant ocular examination findings~* History of depression associated with hospitalization for depression, electroconvulsive therapy, or resulting in prolonged absence from work and/or significant disruption of daily functions~* Suicidal or homicidal ideations and/or attempt, or history of severe psychiatric disorders~* Clinical diagnosis of substance abuse~* Current history of seizure disorder, stroke, or transient ischemic attack~* Immunologically mediated disease~* Chronic pulmonary disease~* Clinically significant cardiac abnormalities/dysfunction~* Active clinical gout within the last year~* Hemoglobinopathy or myelodysplastic syndromes~* History of organ transplants including hematopoietic stem cell transplants~* Poor venous access~* Indwelling venous catheter~* History of gastric surgery or malabsorption disorders~* Severe concurrent disease~* Evidence of active or suspected malignancy, or a history of malignancy, ≤5 years before~* Pregnant, lactating, expecting to conceive or donate eggs~* Male participant with pregnant female partner~* Member/family member of the investigational study or sponsor staff directly involved with this study~* Evidence or history of chronic hepatitis not caused by HCV~Part A~* Not treatment-naïve~* Documented to be HIV positive~* Taking or planning to take significant inducers or inhibitors of CYP3A4 substrates or herbal supplements 2 weeks prior to start of study medications~Parts B, C, and D~* Previously received any HCV direct-acting antivirals~* Requiring, or likely to require, chronic systemic administration of corticosteroids during the course of the trial~* For participants diagnosed with diabetes mellitus, documented HbA1c \>8.5%

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A1: TN NC Grazoprevir 100 mg + Elbasvir 20 mg + RBV-12 wk (Type: EXPERIMENTAL): GT1a and GT1b participants receive Grazoprevir 100 mg tablet orally once daily (QD) for 12 weeks, Elbasvir 20 mg capsule and Placebo capsule orally QD for 12 weeks, RBV capsules orally twice daily (BID) for 24 weeks at a total daily dose from 800 to 1400 mg based on participant weight
- A2: TN NC Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk (Type: EXPERIMENTAL): GT1a and GT1b participants receive Grazoprevir 100 mg tablet orally QD for 12 weeks, Elbasvir 50 mg capsule and Placebo capsule orally QD for 12 weeks, RBV capsules orally BID for 24 weeks at a total daily dose from 800 to 1400 mg based on participant weight
- A3: TN NC/GT1b Grazoprevir 100 mg + Elbasvir 50 mg-12 wk (Type: EXPERIMENTAL): GT1b only participants receive Grazoprevr 100 mg tablet orally QD for 12 weeks, Elbasvir 50 mg capsule orally QD for 12 weeks
- B1: TN NC/GT1a Grazoprevir 100 mg + Elbasvir 50 mg + RBV-8 wk (Type: EXPERIMENTAL): GT1a only participants receive Grazoprevir 100 mg tablet orally QD for 8 weeks, Elbasvir 50 mg capsule orally QD for 8 weeks, RBV capsules orally BID for 8 weeks at a total daily dose from 800 to 1400 mg based on participant weight
- B2: TN NC Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk (Type: EXPERIMENTAL): GT1a/non-a participants receive Grazoprevir 100 mg tablet orally QD for 12 weeks, Elbasvir 50 mg capsule orally QD for 12 weeks, RBV capsules orally BID for 12 weeks at a total daily dose from 800 to 1400 mg based on participant weight
- B3: TN NC/GT1a Grazoprevir 100 mg + Elbasvir 50 mg-12 wk (Type: EXPERIMENTAL): GT1a only participants receive Grazoprevir 100 mg tablet orally QD for 12 weeks, Elbasvir 50 mg capsule orally QD for 12 weeks
- B4: TN C Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk (Type: EXPERIMENTAL): GT1a/non-a participants receive Grazoprevir 100 mg tablet orally QD for 12 weeks, Elbasvir 50 mg capsule orally QD for 12 weeks, RBV capsules orally BID for 12 weeks at a total daily dose from 800 to 1400 mg based on participant
- B5: TN C Grazoprevir 100 mg + Elbasvir 50 mg for 12 wk (Type: EXPERIMENTAL): GT1a/non-a participants receive Grazoprevir 100 mg tablet orally QD for 12 weeks, Elbasvir 50 mg capsule orally QD for 12 weeks
- B6: TN C Grazoprevir 100 mg + Elbasvir 50 mg + RBV-18 wk (Type: EXPERIMENTAL): GT1a/non-a participants receive Grazoprevir 100 mg tablet orally QD for 18 weeks, Elbasvir 50 mg capsule orally QD for 18 weeks, RBV capsules orally BID for 18 weeks at a total daily dose from 800 to 1400 mg based on participant weight
- B7: TN C Grazoprevir 100 mg + Elbasvir 50 mg-18 wk (Type: EXPERIMENTAL): GT1a/non-a participants receive Grazoprevir 100 mg tablet orally QD for 18 weeks, Elbasvir 50 mg capsule orally QD for 18 weeks
- B8: NR Grazoprevir 100 mg + Elbasvir 50 mg +RBV-12 wk (Type: EXPERIMENTAL): GT1a/non-a participants receive Grazoprevir 100 mg tablet orally QD for 12 weeks, Elbasvir 50 mg capsule orally QD for 12 weeks, RBV capsules orally BID for 12 weeks at a total daily dose from 800 to 1400 mg based on participant weight
- B9: NR Grazoprevir 100 mg + Elbasvir 50 mg-12 wk (Type: EXPERIMENTAL): GT1a/non-a participants receive Grazoprevir 100 mg tablet orally QD for 12 weeks, Elbasvir 50 mg capsule orally QD for 12 weeks
- B10: NR Grazoprevir 100 mg + Elbasvir 50 mg + RBV-8 wk (Type: EXPERIMENTAL): GT1a/non-a participants receive Grazoprevir 100 mg tablet orally QD for 18 weeks, Elbasvir 50 mg capsule orally QD for 18 weeks, RBV capsules orally BID for 18 weeks at a total daily dose from 800 to 1400 mg based on participant weight
- B11: NR Grazoprevir 100 mg + Elbasvir 50 mg-18 wk (Type: EXPERIMENTAL): GT1a/non-a participants receive Grazoprevir 100 mg tablet orally QD for 18 weeks, Elbasvir 50 mg capsule orally QD for 18 weeks
- B12: TN HIV NC Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk (Type: EXPERIMENTAL): GT1a/non-a participants receive Grazoprevir 100 mg tablet orally QD for 12 weeks, Elbasvir 50 mg capsule orally QD for 12 weeks, RBV capsules orally BID for 12 weeks at a total daily dose from 800 to 1400 mg based on participant weight
- B13: TN HIV NC Grazoprevir 100 mg + Elbasvir 50 mg-12 wk (Type: EXPERIMENTAL): GT1a/non-a participants receive Grazoprevir 100 mg tablet orally QD for 12 weeks, Elbasvir 50 mg capsule orally QD for 12 weeks
- C1: TN NC/GT1b Grazoprevir 100 mg + Elbasvir 50 mg + RBV-8 wk (Type: EXPERIMENTAL): GT1b participants receive Grazoprevir 100 mg tablet orally QD for 8 weeks, Elbasvir 50 mg capsule orally QD for 8 weeks, and RBV capsules orally BID for 8 weeks at a total daily dose from 800 to 1400 mg based on participant weight.
- C2: TN NC/GT1b Grazoprevir 100 mg + Elbasvir 50 mg-8 wk (Type: EXPERIMENTAL): GT1b participants receive Grazoprevir 100 mg tablet orally QD for 8 weeks and Elbasvir 50 mg capsule orally QD for 8 weeks
- D1: TN NC/GT3 Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk (Type: EXPERIMENTAL): GT3 participants receive Grazoprevir 100 mg tablet orally QD for 12 weeks, Elbasvir 50 mg capsule orally QD for 12 weeks, and RBV capsules orally BID for 12 weeks at a total daily dose from 800 to 1400 mg based on participant weight
- D2: TN NC/GT3 Grazoprevir 100 mg + Elbasvir 50 mg + RBV-18 wk (Type: EXPERIMENTAL): GT3 participants receive Grazoprevir 100 mg tablet orally QD for 18 weeks, Elbasvir 50 mg capsule orally QD for 18 weeks, and RBV capsules orally BID for 18 weeks at a total daily dose from 800 to 1400 mg based on participant weight

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete